Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.

Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Abstract Text:

    OBJECTIVES: Some juvenile dermatomyositis (JDM) patients have a disease course which is refractory to multiple drug treatments. Prolonged disease activity is associated with increased mortality and morbidity. TNF-alpha has been identified in high levels in JDM patients who have a long disease course and calcinosis. We assessed the response of five refractory JDM patients to the anti-TNF-alpha monoclonal antibody, infliximab. METHODS: For all five patients intravenous infliximab was initially given at a dose of 3 mg/kg. Further doses were then given at weeks 2, 6 and every 8 weeks thereafter. The dose and frequency were tailored in accordance with clinical response. Clinical and laboratory data were collected prospectively. RESULTS: We report results between 8 and 30 months after starting infliximab. Improvements were seen in all five patients as shown by positive changes in physician visual analogue scale (VAS), Childhood Myositis Assessment Score (CMAS), Childhood Health Assessment Questionnaire (CHAQ), joint range of movement and, in some, regression of calcinosis and skin signs. There were no major side effects observed with addition of infliximab to the therapeutic regime. CONCLUSIONS: Major clinical benefit was demonstrated after the initiation of infliximab in all five cases of refractory JDM.

    Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Publishing Authors By Initials

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Rheumatology (Oxford, England)

    VOLUME: 47

    Page Numbers: 877-80

    Journal Abbreviation: Rheumatology (Oxford)

    ISSN: 1462-0332

    DAY: 9

    MONTH: 04

    YEAR: 2008

    Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 100883501

    Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.

    AFFILIATION: Juvenile Dermatomyositis Research Centre, Institute of Child Health UCL, 30 Guilford Street, London WC1N 1EH, UK. c.pilkington@ich.ucl.ac.uk

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Rheumatology (Oxford)

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News